Investment Ratings - Integra LifeSciences (IART): Underweight [4] - Inspire Medical (INSP): Overweight [4] - Insulet Corp (PODD): Overweight [4] - Enovis (ENOV): Neutral [4] - Haemonetics (HAE): Overweight [4] - TransMedics Group (TMDX): Neutral [4] - Zimmer Biomet (ZBH): Overweight [4] Core Insights - The MedTech sector is experiencing mixed earnings reports, with several companies expected to beat or miss their earnings estimates [1] - Integra LifeSciences faces challenges due to ongoing operational issues, limiting its ability to offset higher component costs and tariffs, leading to a downward revision in EPS guidance [4] - Inspire Medical has a strong track record of beating revenue expectations and is expected to continue this trend, with a focus on the launch of Inspire 5 [5][7] - Insulet Corp has pre-announced a top-line beat and guidance raise, indicating strong performance in new patient starts and international rollout of Omnipod 5 [14][17] - Enovis is expected to deliver modest upside in earnings, supported by positive market trends in orthopedics [11][12] - Haemonetics is projected to outperform on margins and adjusted EPS, driven by a favorable product mix and cost leverage [15] - TransMedics is anticipated to report strong growth in organ transplant volumes, with limited exposure to macroeconomic challenges [20][22] Company Summaries Integra LifeSciences (IART) - Historical performance shows a 55% beat rate on top-line and 73% on bottom-line, with an average EPS beat of $0.05 [2] - Expected sales of $381.2 million, reflecting a 4.5% organic decline, with EPS forecasted at $0.43 [4] Inspire Medical (INSP) - Historical performance indicates an 85% beat rate on top-line and a 74% positive stock reaction [5] - Anticipated strong performance in new patient starts and potential upside in EPS due to better gross margins [17] Insulet Corp (PODD) - Historical performance shows a 93% beat rate on top-line and a mixed stock reaction [14] - Expected to raise full-year guidance following a strong quarter, with EPS forecasted at $0.86 [17] Enovis (ENOV) - Historical performance indicates a 48% beat rate on top-line and a 90% on bottom-line [10] - Expected sales of $558.2 million, with EPS forecasted at $0.76, reflecting a positive outlook in orthopedics [12] Haemonetics (HAE) - Historical performance shows a 61% beat rate on top-line and 85% on bottom-line [13] - Forecasted adjusted EPS of $1.24, driven by improved margins and a favorable product mix [15] TransMedics Group (TMDX) - Historical performance indicates an 83% revenue beat rate, with shares showing volatility post-earnings [18] - Expected sales growth of 28%, with a focus on strong demand in organ transplant procedures [20][22] Zimmer Biomet (ZBH) - Historical performance shows a 59% beat rate on revenues and 82% on earnings [6] - Anticipated revenue of $194 million, with a focus on maintaining growth despite macroeconomic challenges [7]